{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"8.4","value":"4.1"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"4.9","value":"3.9"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"4.2","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"Evaluate the efficacy endpoints of Progression-Free Survival by the IRC for Cohorts 2 \\& 4 and by the investigator for Cohort 1 per RECIST v1.1","dispersionType":"95% Confidence Interval","groups":[{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)","id":"OG000","title":"Cohort 2"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)","id":"OG001","title":"Cohort 4"},{"description":"Non-cryopreserved LN-144 (Gen 1 infusion product)","id":"OG002","title":"Cohort 1"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set is defined as patients who received the lifileucel infusion that met product manufacturing specifications. Due to the small number of patients this outcome measure was not analyzed for Cohort 3 per the statistical analysis plan.","reportingStatus":"POSTED","timeFrame":"Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months","title":"Disease Assessment for Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}